Content
All Posts > Content under Pharma/Biotech
Week In Review: Everest In-Licenses An ADC From Immunomedics In $835 Million Agreement, A China Record For A Single Asset
Article By:
ChinaBio® Today
Read
Saturday, May 4, 2019 5:44 PM EDT
Everest Medicines II of Shanghai, a C-Bridge company, agreed to pay up to a record $835 million in upfront and milestone payments for China rights to an Immunomedics ADC.
Finally A Real Cancer Diagnosis Breakthrough?
Article By:
Terry Chrisomalis
Read
Friday, May 3, 2019 8:04 AM EDT
TOMDF is a diagnostics company that utilizes blood tests for early detection of cancer and neurodegenerative diseases. But is it a good investment? I took a deeper look and reached out to the company's CEO, Herman Weiss, to get the facts.
In "Stunning Decision" Bayer Shareholders Dump CEO Over Disastrous Monsanto Purchase
Article By:
Tyler Durden
Read
Sunday, April 28, 2019 12:24 PM EDT
Bayer survived World War II but it may not survive the worst acquisition in its history: the disastrous $63 billion purchase of Monsanto in 2018, which also brought the carcinogenic weed-killer Roundup and countless lawsuits and legal charges.
In this article: BAYRY
Week In Review: Eddingpharm To Pay $375 Million For Two Lilly Antibiotics And A Suzhou Manufacturing Facility
Article By:
ChinaBio® Today
Read
Saturday, April 27, 2019 4:20 PM EDT
Eddingpharm, a Hong Kong-headquartered China in-licensing company, agreed to pay $375 million to acquire China rights for two off-patent antibiotics from Lilly and the Suzhou factory that makes the antibiotics.
12 Monster Stock Market Predictions For The Week Of April 22
Article By:
Michael J. Kramer
Read
Sunday, April 21, 2019 7:40 PM EDT
It will be a big week for earnings. It will also be a big week because we will get our first official reading for first quarter GDP growth and estimates are for 2%.
A Trio Of Income Favorites
Article By:
MoneyShow.com
Read
Saturday, April 20, 2019 10:19 PM EDT
Income expert Harry Domash maintains a wide variety of portfolios designed to help investors seeking a diversified portfolio of dividend stocks. Here he highlights a trio of yield-oriented favorites.
Week In Review: Chi-Med Plans $500 Million Hong Kong IPO
Article By:
ChinaBio® Today
Read
Saturday, April 20, 2019 4:48 PM EDT
Hutchison China MediTech filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, where it has a market capitalization of over $4 billion. The IPO is expected to raise between $300 million and $500 million.
Best Stock Pick From The 2018 Sohn Conference
Article By:
Insider Monkey
Read
Saturday, April 20, 2019 4:24 PM EDT
Stocks pitched at investment conferences aren’t necessarily the “best” stock picks of hedge funds as they sell them stocks afterward to create room for their real best ideas. However, these stocks still outperformed the market by an average of 7%.
Research Report: Akebia Therapeutics, Inc.
Article By:
Elle Investments
Read
Saturday, April 20, 2019 3:11 PM EDT
As of 4Q18, AKBA had cash of $322M. Additionally, AKBA is eligible to receive over $150M in development and regulatory milestones from its collaboration partners.
In this article: AKBA
Rexahn's Deal With China For RX-3117 Candidate Moves It Back On The Right Track
Article By:
Terry Chrisomalis
Read
Tuesday, April 16, 2019 4:43 PM EDT
Rexahn Pharma generates a deal in Greater China for its clinical cancer product. Here's what you need to know...